A CRISPR-Cas13a Based Strategy That Tracks and Degrades Toxic RNA in Myotonic Dystrophy Type 1 - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Frontiers in Genetics Année : 2020

A CRISPR-Cas13a Based Strategy That Tracks and Degrades Toxic RNA in Myotonic Dystrophy Type 1

Résumé

Cas13a, an effector of type VI CRISPR-Cas systems, is an RNA guided RNase with multiplexing and therapeutic potential. This study employs the Leptotrichia shahii ( Lsh ) Cas13a and a repeat-based CRISPR RNA (crRNA) to track and eliminate toxic RNA aggregates in myotonic dystrophy type 1 (DM1) – a neuromuscular disease caused by CTG expansion in the DMPK gene. We demonstrate that Lsh Cas13a cleaves CUG repeat RNA in biochemical assays and reduces toxic RNA load in patient-derived myoblasts. As a result, Lsh Cas13a reverses the characteristic adult-to-embryonic missplicing events in several key genes that contribute to DM1 phenotype. The deactivated Lsh Cas13a can further be repurposed to track RNA-rich organelles within cells. Our data highlights the reprogrammability of Lsh Cas13a and the possible use of Cas13a to target expanded repeat sequences in microsatellite expansion diseases.
Fichier principal
Vignette du fichier
2021 CRIPSR13.pdf (4.76 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03410640 , version 1 (15-11-2021)

Identifiants

Citer

Nan Zhang, Brittani Bewick, Guangbin Xia, Denis Furling, Tetsuo Ashizawa. A CRISPR-Cas13a Based Strategy That Tracks and Degrades Toxic RNA in Myotonic Dystrophy Type 1. Frontiers in Genetics, 2020, 11, ⟨10.3389/fgene.2020.594576⟩. ⟨hal-03410640⟩
28 Consultations
33 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More